Identifying Patients With BCG-Unresponsive High-Risk NMIBC Suitable for Treatment With TAR-200
TAR-200 is being studied for carcinoma in situ with or without papillary disease since it addresses diffuse CIS that cannot be surgically removed, though future trials will expand to papillary disease as adjuvant therapy like BCG, with the goal of extending the disease-free period before potentially reintroducing therapy as needed.
EP: 1.An Overview of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer (NMIBC)
EP: 2.Current Standard-of-Care Treatment for Patients With BCG-Unresponsive High-Risk NMIBC
EP: 3.Overview of the Mechanism of Action of TAR-200 in Patients With BCG-Unresponsive High-Risk NMIBC
EP: 4.Safety Data From the Phase 2B SunRISe-2 Study of TAR-200 in BCG-Unresponsive High-Risk NMIBC
EP: 5.Identifying Patients With BCG-Unresponsive High-Risk NMIBC Suitable for Treatment With TAR-200
EP: 6.Other Key Trials in the Treatment of BCG-Unresponsive High-Risk NMIBC
EP: 7.Clinical Pearls for Oncologists Treating Patients With BCG-Unresponsive NMIBC
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
